[go: up one dir, main page]

AR044453A1 - Derivados de metoxi-pirazin-tienil sulfonamida - Google Patents

Derivados de metoxi-pirazin-tienil sulfonamida

Info

Publication number
AR044453A1
AR044453A1 ARP040101849A ARP040101849A AR044453A1 AR 044453 A1 AR044453 A1 AR 044453A1 AR P040101849 A ARP040101849 A AR P040101849A AR P040101849 A ARP040101849 A AR P040101849A AR 044453 A1 AR044453 A1 AR 044453A1
Authority
AR
Argentina
Prior art keywords
tienil
pirazin
metoxi
sulfonamide derivatives
chlorine
Prior art date
Application number
ARP040101849A
Other languages
English (en)
Inventor
Antonio Mete
Barry Teobald
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR044453A1 publication Critical patent/AR044453A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Proceso de preparación, composición farmacéutica y usos. Reivindicación 1: Un compuesto caracterizado porque es de la fórmula (1), y sus sales o solvatos aceptables para uso farmacéutico, en el cual: R1 es hidrógeno o cloro; y R2 es hidrógeno, metilo, cloro o bromo.
ARP040101849A 2003-06-04 2004-05-28 Derivados de metoxi-pirazin-tienil sulfonamida AR044453A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301650A SE0301650D0 (sv) 2003-06-04 2003-06-04 Novel compounds

Publications (1)

Publication Number Publication Date
AR044453A1 true AR044453A1 (es) 2005-09-14

Family

ID=29212389

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040101849A AR044453A1 (es) 2003-06-04 2004-05-28 Derivados de metoxi-pirazin-tienil sulfonamida

Country Status (8)

Country Link
US (1) US20060128723A1 (es)
EP (1) EP1633744A1 (es)
JP (1) JP2006526620A (es)
AR (1) AR044453A1 (es)
SE (1) SE0301650D0 (es)
TW (1) TW200510398A (es)
UY (1) UY28344A1 (es)
WO (1) WO2004108717A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI328007B (en) * 2002-01-16 2010-08-01 Astrazeneca Ab Novel compounds
SE0301654D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
AU2006237365B2 (en) 2005-04-21 2012-09-20 Merck Serono Sa 2,3 substituted pyrazine sulfonamides as inhibitors of CRTH2
JP5567268B2 (ja) 2005-05-24 2014-08-06 メルク セローノ ソシエテ アノニム Ｃｒｔｈ２の調節剤としての三環系スピロ誘導体
WO2007063935A1 (ja) * 2005-12-02 2007-06-07 Mitsubishi Tanabe Pharma Corporation 芳香族化合物
US20090182140A1 (en) * 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
TW200730512A (en) * 2005-12-12 2007-08-16 Astrazeneca Ab Novel compounds
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
AU2013203369B2 (en) * 2007-09-18 2016-06-02 Cancer Research Technology Ltd Cancer marker and therapeutic target
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
CA2753337A1 (en) * 2009-02-26 2010-09-02 Heather Hobbs Pyrazole derivatives used as ccr4 receptor antagonists
WO2012025474A1 (en) * 2010-08-24 2012-03-01 Glaxo Group Limited Indazole compounds
GB2512857A (en) 2013-04-09 2014-10-15 Cancer Res Technology Cancer biomarker
KR20200104291A (ko) 2017-11-06 2020-09-03 랩트 테라퓨틱스, 인크. 항암제

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
WO2002030357A2 (en) * 2000-10-11 2002-04-18 Chemocentryx, Inc. Compounds and methods for modulating ccr4 function
US20060004010A1 (en) * 2002-07-10 2006-01-05 Hiromu Habashita Ccr4 antagonist and medical use thereof
SE0301654D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) * 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
WO2004108717A1 (en) 2004-12-16
SE0301650D0 (sv) 2003-06-04
JP2006526620A (ja) 2006-11-24
UY28344A1 (es) 2005-01-31
EP1633744A1 (en) 2006-03-15
US20060128723A1 (en) 2006-06-15
TW200510398A (en) 2005-03-16

Similar Documents

Publication Publication Date Title
AR044453A1 (es) Derivados de metoxi-pirazin-tienil sulfonamida
PA8518801A1 (es) Derivados de 2-aminocarbonil-9h-purina
UY28763A1 (es) Compuestos de tetrazol y su uso como antagonistas del receptor de glutamato metabotrópico
UY28026A1 (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos.
CL2004000655A1 (es) Compuestos derivados de piperidin-2-ona 1,6-disustituidos, sus sales, composicion farmaceutica, agonistas del receptor ep4; uso de los compuestos para tratar hipertension ocular, glaucoma.
ATE302775T1 (de) Carbolinderivate
DK1723144T3 (da) Yderligere heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamareceptor-antagonister
UY29437A1 (es) Nuevos antagonistas de cgrp
UY26727A1 (es) Derivados de tropano útiles en terapia
CY1109656T1 (el) Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης
PA8575401A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso
UY27446A1 (es) Nuevos compuestos
HN2002000275A (es) Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados
UY28764A1 (es) Compuestos poliheterocíclicos y su uso como antagonistas del receptor de glutamato metabotrópico
ATE416157T1 (de) Inhibitoren von integrin alpha-v-beta-6
ATE346067T1 (de) Carbolinderivate
GT200500309A (es) Derivados de sulfonilbencilimidazol
ATE300543T1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
AR041339A1 (es) Derivados de tiazolpirimidinona,proceso de preparacion y composiciones farmaceuticas que los contienen
UY28765A1 (es) Compuestos de piperazina acetilínica y su uso como antagonistas del receptor de glutamato metabotrópico
AR039935A1 (es) Formulacion farmaceutica de liberacion inmediata
ATE302776T1 (de) Kondensierte pyridoindolderivate

Legal Events

Date Code Title Description
FB Suspension of granting procedure